Key Points
- ANI Pharmaceuticals VP Meredith Cook sold 500 shares on June 12 at an average price of $82.03, totaling $41,015. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Cook still owned 77,890 shares valued at about $6.39 million, and the sale represented a modest 0.64% reduction in her holdings.
- ANI Pharmaceuticals recently posted strong quarterly results, with EPS of $2.05 beating estimates and revenue of $237.46 million topping forecasts. Analysts currently rate the stock a “Moderate Buy” with a consensus price target of $107.33.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $82.03, for a total transaction of $41,015.00. Following the completion of the transaction, the vice president directly owned 77,890 shares in the company, valued at $6,389,316.70. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.16, for a total transaction of $39,080.00.
- On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.95, for a total transaction of $38,975.00.
ANI Pharmaceuticals Price Performance
Shares of ANIP opened at $82.29 on Tuesday. The firm has a market capitalization of $1.87 billion, a PE ratio of 20.83 and a beta of 0.44. The company's 50-day moving average is $79.88 and its 200-day moving average is $79.41. ANI Pharmaceuticals, Inc. has a fifty-two week low of $62.14 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company's revenue was up 20.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current year.
Hedge Funds Weigh In On ANI Pharmaceuticals
Hedge funds have recently bought and sold shares of the company. Hantz Financial Services Inc. increased its holdings in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 237 shares during the period. KBC Group NV bought a new position in ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. 76.05% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently commented on ANIP shares. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $107.33.
Check Out Our Latest Stock Analysis on ANI Pharmaceuticals
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
